173 related articles for article (PubMed ID: 26649681)
1. Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer.
Chen KL; Lin CC; Cho YT; Yang CW; Sheen YS; Tsai HE; Chu CY
JAMA Dermatol; 2016 Mar; 152(3):340-2. PubMed ID: 26649681
[No Abstract] [Full Text] [Related]
2. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
Kiyohara Y; Yamazaki N; Kishi A
J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
Burotto M; Manasanch EE; Wilkerson J; Fojo T
Oncologist; 2015 Apr; 20(4):400-10. PubMed ID: 25795635
[TBL] [Abstract][Full Text] [Related]
4. Overview of current systemic management of EGFR-mutant NSCLC.
Hsu WH; Yang JC; Mok TS; Loong HH
Ann Oncol; 2018 Jan; 29(suppl_1):i3-i9. PubMed ID: 29462253
[TBL] [Abstract][Full Text] [Related]
5. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Takeda M; Okamoto I; Nakagawa K
Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous adverse events of epidermal growth factor receptor inhibitors: A retrospective review of 99 cases.
Chanprapaph K; Pongcharoen P; Vachiramon V
Indian J Dermatol Venereol Leprol; 2015; 81(5):547. PubMed ID: 25994883
[TBL] [Abstract][Full Text] [Related]
7. [Cutaneous side effects of EGFR inhibitors--appearance and management].
Wollenberg A; Kroth J; Hauschild A; Dirschka T
Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
[TBL] [Abstract][Full Text] [Related]
8. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
10. Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.
Cho YT; Chen KL; Sheen YS; Yang CW; Liau JY; Cheng YP; Chu CY
JAMA Dermatol; 2017 Sep; 153(9):906-910. PubMed ID: 28538945
[TBL] [Abstract][Full Text] [Related]
11. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
Eames T; Landthaler M; Karrer S
Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
[No Abstract] [Full Text] [Related]
12. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
Murakami H; Tamura T; Takahashi T; Nokihara H; Naito T; Nakamura Y; Nishio K; Seki Y; Sarashina A; Shahidi M; Yamamoto N
Cancer Chemother Pharmacol; 2012 Apr; 69(4):891-9. PubMed ID: 22071596
[TBL] [Abstract][Full Text] [Related]
13. Rosaceiform eruption induced by erlotinib.
Patrizi A; Bianchi F; Neri I
Dermatol Ther; 2008 Oct; 21 Suppl 2():S43-5. PubMed ID: 18837734
[TBL] [Abstract][Full Text] [Related]
14. Acneiform reaction to erlotinib.
Schalock PC; Zug KA
Dermatitis; 2007 Dec; 18(4):230-1. PubMed ID: 18021605
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib-Induced Transverse Fissure-Like Skin Lesions of Fingers.
Sadeghi M; Loftus R; Dasanu CA
Conn Med; 2016 Sep; 80(7):405-407. PubMed ID: 29782127
[TBL] [Abstract][Full Text] [Related]
16. [Acneiforme rash in woman with pulmonary adenocarcinoma].
Navarro Martín M; Rodríguez Sánchez C; Delgado Fernández C; Mezquita Pérez L; Cruz Hernández JJ
Rev Clin Esp; 2008 May; 208(5):251-2. PubMed ID: 18457638
[No Abstract] [Full Text] [Related]
17. Scalp pustules in a patient receiving chemotherapy.
Chiu HY; Chiu HC
JAMA; 2013 Sep; 310(10):1068-9. PubMed ID: 24026603
[No Abstract] [Full Text] [Related]
18. Acneiform eruption induced by Iressa (gefitinib) tablets used to treat non-small cell lung cancer.
Warthan MM; Jumper CA; Smith JL
J Drugs Dermatol; 2004; 3(5):569-70. PubMed ID: 15552613
[TBL] [Abstract][Full Text] [Related]
19. [Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors].
Bodet D; Bartralot R; Mollet J; Heras C; García-Patos V
Actas Dermosifiliogr; 2006 Mar; 97(2):148-9. PubMed ID: 16595122
[No Abstract] [Full Text] [Related]
20. Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
Nonagase Y; Okamoto K; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Shimizu T; Tsurutani J; Nakagawa K
Anticancer Drugs; 2016 Mar; 27(3):251-3. PubMed ID: 26575001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
